Gujarat Themis Biosyn Completes Acquisition of MicroBiopharm Japan Co.

Gujarat Themis Biosyn Strengthens Global Footprint with Acquisition of MicroBiopharm Japan

The acquisition positions Gujarat Themis Biosyn as a key player in the fermentation-based CDMO landscape, enhancing its capabilities and market reach.

Details of the Acquisition

Gujarat Themis Biosyn (GTBL) has acquired 100% equity shareholding in MicroBiopharm Japan Co. (MBJ) through its wholly owned subsidiary, Themis Biosyn Japan. The deal, initially announced on May 22, 2026, was finalized after obtaining all necessary regulatory approvals. The total consideration for the acquisition was JPY 21.5 billion, financed through a strategic mix of debt and equity. This acquisition is anticipated to be accretive to GTBL’s earnings per share (EPS).

Strategic Importance of MBJ

MicroBiopharm Japan has a robust operational history, boasting over 60 years of experience in the biopharmaceutical industry. The company operates three GMP-compliant manufacturing plants and has a strong track record with both the FDA and PMDA. For the fiscal year 2026, MBJ reported revenues of JPY 9.5 billion, with a diverse business mix that includes proprietary APIs, CDMO services, and developed pharmaceuticals. Notably, approximately 40% of its revenue is generated from international markets, highlighting its global reach.

Leadership and Future Directions

Dr. Sachin Patel, Managing Director of GTBL, expressed optimism regarding the acquisition, describing it as a pivotal step towards establishing GTBL as a fermentation-based, globally integrated Contract Development and Manufacturing Organization (CDMO). He emphasized that MBJ’s extensive fermentation expertise and established relationships with leading pharmaceutical companies will enable GTBL to expand its offerings in oncology, immunosuppressants, peptides, and advanced biologics. The existing MBJ management team will continue to lead operations, ensuring a seamless integration and continuity in service delivery.

Market Implications

This acquisition is expected to bolster GTBL’s position in the competitive biopharmaceutical market. By leveraging MBJ’s capabilities, GTBL can enhance its service offerings and potentially attract new clients, particularly in the lucrative oncology and biologics sectors. The integration of MBJ’s advanced manufacturing processes with GTBL’s existing infrastructure could lead to increased operational efficiencies and cost savings, further strengthening its market position.

Key Highlights

• Gujarat Themis Biosyn acquires 100% stake in MicroBiopharm Japan for JPY 21.5 billion.
• MBJ has over 60 years of experience and operates three GMP-compliant plants.
• The acquisition is expected to be EPS accretive for GTBL.
• Approximately 40% of MBJ’s revenue comes from international markets.
• Existing MBJ management will continue to lead operations post-acquisition.

Investor Note: The successful acquisition of MicroBiopharm Japan positions Gujarat Themis Biosyn for significant growth in the biopharmaceutical sector, leveraging enhanced capabilities and market reach to drive future revenue growth.